Last checked at 
LONDON (Alliance News) - ValiRx PLC said Tuesday that it has submitted an application to the Medicines and Healthcare Products Regulatory Agency for a phase I/II extended clinical study, or trial, of VAL201 in people with cancer.
VAL201 is ValiRx's leading anti-cancer therapeutic candidate.
The life science company, which focuses on cancer diagnostics and therapeutics for personalised medicines, said that it plans to conduct "A Phase I/II, dose escalation study to assess the safety and tolerability of VAL201 in patients with locally advanced or metastatic prostate cancer and other advanced solid tumours."
The study will take place at University College London Hospital when all the consents have been given, said the company.
Shares in ValiRx were trading 1.49% higher at 0.34 pence per share Tuesday morning.
By Alice Attwood; aliceattwood@alliancenews.com; @AliceAtAlliance
Copyright 2014 Alliance News Limited. All Rights Reserved.
